X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Reshaping Parenteral Drug Production Amid COVID Disruption

Content Team by Content Team
15th August 2023
in Drug Development, News
NIH begins study of allergic reactions to Covid-19 vaccines

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The parenteral drug manufacturing process is anchored by the Supply Chain. The impact of COVID-19 has influenced both positively and negatively the production of contemporary parenteral drugs. Many manufacturers have structured their systems around the lean Just-In-Time (JIT) production method, which maintains minimal inventory to match customer demand efficiently.

An issue that emerged in parenteral manufacturing, as well as in other sectors like semiconductors, was inventory stock-outs. The focus on minimal inventory left companies vulnerable to market fluctuations during the pandemic. Nevertheless, JIT production incorporates strategies for predicting demand, potential supply chain disruptions, and other factors, making it resilient. Collectively, Contract Development and Manufacturing Organizations (CDMOs), Contract Manufacturing Organizations (CMOs), and Sponsor companies have invested billions to secure common materials’ inventory. This stockpiling, however, has paradoxically led to further shortages and shipping delays due to the intricate interplay of major players’ actions.

The parenteral drug market, notably dominated by monoclonal antibodies (MAbs) accounting for about 21% of revenue, is expected to expand. A report by Fact.MR predicts that the global parenteral drugs market could exceed $802 billion by 2029. The potential for parenteral administration in advanced therapies, such as vaccines targeting various diseases including certain cancers, continues to grow.

Large molecule drugs make up around 52% of the market, with small molecule therapies representing the remaining 48%. The large molecule segment is projected to increase to about 62% in the coming year, driven by high incremental revenue potential. Parenteral routes are increasingly favored, accounting for 40-50% of New Molecular Entity (NME) drug approvals.

Oncology therapeutics comprise the majority of NMEs in the parenteral sector (27.5%), with a notable presence in infectious diseases (10%) and cardiovascular conditions (~5%). The expanding landscape of disease areas and clinical trial phases offers varied opportunities. The mRNA technology market has rapidly grown, with the market capitalization of top mRNA-focused companies soaring from $15 billion to over $300 billion in two years. Beyond COVID-19, mRNA platforms are poised to produce vaccines for other diseases, including personalized cancer treatments. Public acceptance and trends surrounding this technology remain to be seen.

Given the complexity of pharmaceutical fill-finish processes, partnerships between Sponsors and CDMOs/CMOs have proliferated. Fill-finish constitutes a substantial market segment worth more than $3 billion, projected to grow further as therapies advance in the industry pipeline.

In light of these industry dynamics, participating in the network that delivers next-generation therapies to patients is a humbling endeavor. Understanding the underlying trends behind these developments is crucial for informed decision-making, fostering industry connectivity and preparedness for the evolving landscape of drug production.

Previous Post

PPWR Proposal To Shake Up Pharmaceutical Packaging Industry

Next Post

Cancer Research Boosts Small Molecule CDMO Market Expansion

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Cancer Research Boosts Small Molecule CDMO Market Expansion

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In